4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, Emeryville, United States

ibaian Aug. 30 at 4:38 PM

$FDMT 4D-710 for Cystic Fibrosis Lung Disease: Interim data from AEROW clinical trial and program update expected in Q4 2025

0 · Reply

ibaian Aug. 30 at 4:37 PM

$FDMT Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for 4D-150 for the treatment of DME

0 · Reply

ibaian Aug. 30 at 4:35 PM

$FDMT PRISM Phase 1/2 Clinical Trial: 2-year data from Phase 1/2a and 18-month data from Phase 2b cohorts expected in Q4 2025

0 · Reply

Florestan Aug. 28 at 8:18 PM

$FDMT I think retracing after a big move is fairly standard. Reading too much into these moves at your own peril. I think if durability holds, this is the new backbone therapy for wAMD.

0 · Reply

caronte Aug. 28 at 7:38 PM

$FDMT why do shorts still concentrate on this ticker given the limited amount of weak hands and massive presence of institutional investors ? you short It with small volume price moves on supersmall volume but Who Is gonna sell ? swing traders? not clear why this should be shorted with huge amount of overvalued tickers in the market. If there Is trust in the ability to generate value in the segmento of this Company and measurable results why they short It on no news? Of

1 · Reply

ReturnOfEsquire Aug. 28 at 6:12 PM

$FDMT

1 · Reply

ReturnOfEsquire Aug. 28 at 3:33 PM

$FDMT The only thing that has changed is the pumpers left. So volume is dry, which makes it an easy short. Admittedly, I intended to swing some out, but I got caught up in the "partnership" narrative. That said, this is still a very strong conviction play for me. We will be getting at least two updates in the next 120 days. Hang in there. It's a long play. We all knew that. And I still believe a DME partnership gets announced, but I don’t know when.

0 · Reply

ReturnOfEsquire Aug. 28 at 5:04 AM

$FDMT Another new job listing.

1 · Reply

caronte Aug. 27 at 8:32 AM

$FDMT stay long!

0 · Reply

caronte Aug. 27 at 8:28 AM

$FDMT apparently the very very same copy/paste message of the (paid or fake) user "biotech" is present also on Twitter/X with another username. This apparently seems to confirm that there is active willingness to generate informative disruption with fake news (to short it?). I would really appreciate if shorts (or naked shorts) and manipulator would go away asap and let the company work. Really hope the SEC, if the hypothesis above is correct, will wake up somehow.

0 · Reply

4DMT to Participate in Upcoming Investor Conferences

Aug 15, 2025, 4:05 PM EDT - 15 days ago

4DMT Announces New Employment Inducement Grants

Aug 11, 2025, 8:00 AM EDT - 19 days ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 24 days ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 10:29 AM EDT - 4 weeks ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Jul 31, 2025, 4:05 PM EDT - 4 weeks ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 5 weeks ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 2 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025, 4:05 PM EDT - 4 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 4 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Mar 10, 2025, 8:00 AM EDT - 6 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 6 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 6 months ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 7 months ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 7 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 10 months ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 10 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 10 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 10 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 10 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

Oct 12, 2024, 11:00 AM EDT - 11 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 10, 2024, 11:00 AM EDT - 11 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Oct 8, 2024, 11:00 AM EDT - 11 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 6, 2024, 11:00 AM EDT - 11 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 4, 2024, 12:35 PM EDT - 11 months ago

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 4, 2024, 11:00 AM EDT - 11 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

$Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Oct 3, 2024, 11:00 AM EDT - 11 months ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

Sep 30, 2024, 11:00 AM EDT - 11 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out

Sep 27, 2024, 11:00 AM EDT - 1 year ago

Shareholders Are Urged To Take Part In The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Violating Securities Laws

Sep 26, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Invites Affected Investors To Join

Sep 24, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And Investors Are Urged To Assist The Schall Law Firm

$The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Sep 23, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

Sep 23, 2024, 8:00 AM EDT - 1 year ago

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

Sep 22, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

Sep 20, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. May Have Engaged In Securities Fraud And The Schall Law Firm Urges Investors To Join An Inquiry

ibaian Aug. 30 at 4:38 PM

$FDMT 4D-710 for Cystic Fibrosis Lung Disease: Interim data from AEROW clinical trial and program update expected in Q4 2025

0 · Reply

ibaian Aug. 30 at 4:37 PM

$FDMT Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for 4D-150 for the treatment of DME

0 · Reply

ibaian Aug. 30 at 4:35 PM

$FDMT PRISM Phase 1/2 Clinical Trial: 2-year data from Phase 1/2a and 18-month data from Phase 2b cohorts expected in Q4 2025

0 · Reply

Florestan Aug. 28 at 8:18 PM

$FDMT I think retracing after a big move is fairly standard. Reading too much into these moves at your own peril. I think if durability holds, this is the new backbone therapy for wAMD.

0 · Reply

caronte Aug. 28 at 7:38 PM

1 · Reply

ReturnOfEsquire Aug. 28 at 6:12 PM

$FDMT

1 · Reply

ReturnOfEsquire Aug. 28 at 3:33 PM

0 · Reply

ReturnOfEsquire Aug. 28 at 5:04 AM

$FDMT Another new job listing.

1 · Reply

caronte Aug. 27 at 8:32 AM

$FDMT stay long!

0 · Reply

caronte Aug. 27 at 8:28 AM

0 · Reply

NFTFlowPro Aug. 27 at 4:56 AM

$FDMT price stabilizing, could attract dip buyers.

0 · Reply

Emremumcu01 Aug. 26 at 2:44 PM

$FDMT Another atrocious day … I’m done watching this until some news comes out.

1 · Reply

BestNwest Aug. 26 at 1:49 AM

$AXIL,$ETHZ,$FDMT on watch...

0 · Reply

BestNwest Aug. 26 at 1:34 AM

$FDMT i just buy this morning, seem to make a move...

0 · Reply

vu_jade Aug. 26 at 1:31 AM

$FDMT buy the dips

0 · Reply

caronte Aug. 25 at 3:31 PM

$FDMT let the shorts be squeezed . 40$ short term 100$+ long term. Go green

0 · Reply

ReturnOfEsquire Aug. 25 at 2:54 PM

$FDMT Looking at everything again, I suspect there is no hurry with DME since we need to complete both wet AMDs and use that safety data to support the DME BLA. Unless we can advance the second wet AMD P3 completion date, the company is probably fine waiting until EOY or even early 2026 to start DME P3.

1 · Reply

Emremumcu01 Aug. 25 at 1:43 PM

$FDMT this volume is dog water to start the day , what is going on

0 · Reply

ReturnOfEsquire Aug. 25 at 1:31 AM

$FDMT The hiring continues. https://4dmoleculartherapeutics.com/careers/?gh_jid=4596245005

1 · Reply

ReturnOfEsquire Aug. 22 at 10:39 PM

$FDMT These closes have been awful. We haven't closed near HOD for some time.

1 · Reply

caronte Aug. 22 at 3:45 PM

$FDMT come on, 40$ is our short term destination

0 · Reply

caronte Aug. 22 at 1:45 PM

$FDMT

0 · Reply

Market Cap	287.68M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	342,500
Avg Vol	1,277,830
Day's Range	N/A - N/A
Shares Out	46.70M
Stochastic %K	7%
Beta	2.83
Analysts	Strong Sell
Price Target	$28.78